Aberrant Crypt Foci in the Adenoma Prevention with Celecoxib Trial

Abstract Aberrant crypt foci (ACF) are the earliest visible neoplastic lesions in the colorectum. The natural history of these lesions and their role in the adenoma-carcinoma sequence are unknown. We studied ACF in a subset of patients randomized to placebo (n = 17), celecoxib (200 mg twice daily; n = 15), or celecoxib (400 mg twice daily; n = 13) in the Adenoma Prevention with Celecoxib (APC) trial. Magnification chromoendoscopy was done to identify, count, and biopsy ACF within the rectum at baseline and after 8 to 12 months of treatment. A total of 655 ACF were identified in 45 patients. We examined 70 of these ACF histologically, and all 70 were nondysplastic. Cohort characteristics and APC trial treatment results for substudy patients were similar to those of the overall APC trial. There was no significant modulation of ACF by celecoxib (versus placebo; P = 0.77). Immunohistochemical comparison of ACF with adjacent normal mucosa showed that ACF had an increased proliferative index as determined by Ki-67 (P < 0.0001), but lacked other features of neoplasia such as increased cyclooxygenase-2 expression and microvessel density, nuclear localization of β-catenin, or decreased expression of the tumor suppressors SMAD4, Estrogen Receptor α, or MGMT. Only baseline SMAD4 expression in ACF correlated with posttreatment adenoma recurrence (independent of treatment arm; P = 0.01). The presence or number of nondysplastic ACF did not correlate with a higher risk of synchronous advanced or recurrent adenomas. Our overall results indicated that nondysplastic ACF were not accurate surrogate endpoint biomarkers of recurrent colorectal adenomas in the APC trial.

[1]  R. Stevens,et al.  Epidemiology of colonic aberrant crypt foci: review and analysis of existing studies. , 2007, Cancer letters.

[2]  J. Jass Classification of colorectal cancer based on correlation of clinical, morphological and molecular features , 2007, Histopathology.

[3]  M. Mäkinen,et al.  Colorectal serrated adenocarcinoma , 2007, Histopathology.

[4]  S. Solomon,et al.  Celecoxib for the prevention of sporadic colorectal adenomas. , 2006, The New England journal of medicine.

[5]  S. Solomon,et al.  Celecoxib for the prevention of colorectal adenomatous polyps. , 2006, The New England journal of medicine.

[6]  D. Anagnostakis,et al.  Expression of Smad4 and TGF-β2 in Colorectal Carcinoma , 2006 .

[7]  M. Bertagnolli,et al.  Changes in antitumor response in C57BL/6J-Min/+ mice during long-term administration of a selective cyclooxygenase-2 inhibitor. , 2006, Cancer research.

[8]  R. Fodde,et al.  Smad4 haploinsufficiency in mouse models for intestinal cancer , 2006, Oncogene.

[9]  J. Jass,et al.  Advanced colorectal polyps with the molecular and morphological features of serrated polyps and adenomas: concept of a ‘fusion’ pathway to colorectal cancer , 2006, Histopathology.

[10]  S. Cross,et al.  Role of aberrant crypt foci detected using high‐magnification‐chromoscopic colonoscopy in human colorectal carcinogenesis , 2005, Journal of gastroenterology and hepatology.

[11]  V. Steele,et al.  Modulation by celecoxib and difluoromethylornithine of the methylation of DNA and the estrogen receptor-alpha gene in rat colon tumors. , 2004, Carcinogenesis.

[12]  P. Adegboyega,et al.  Subepithelial Myofibroblasts Express Cyclooxygenase-2 in Colorectal Tubular Adenomas , 2004, Clinical Cancer Research.

[13]  M. Byrne,et al.  The relationship between cyclooxygenase-2 expression and characteristics of malignant transformation in human colorectal adenomas , 2004, European journal of gastroenterology & hepatology.

[14]  A. Nissan,et al.  Suppressive effect of aspirin on aberrant crypt foci in patients with colorectal cancer , 2003, Gut.

[15]  G. Beck,et al.  A randomized trial of aspirin to prevent colorectal adenomas. , 2003, The New England journal of medicine.

[16]  Christopher J Gostout,et al.  Endoscopic identification and quantification of aberrant crypt foci in the human colon. , 2002, Gastrointestinal endoscopy.

[17]  J. Masferrer Approach to angiogenesis inhibition based on cyclooxygenase-2. , 2001, Cancer journal.

[18]  B. Levin,et al.  The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. , 2000, The New England journal of medicine.

[19]  V. Steele,et al.  Efficacy of potential chemopreventive agents on rat colon aberrant crypt formation and progression. , 2000, Carcinogenesis.

[20]  Junji Kato,et al.  Aberrant crypt foci of the colon as precursors of adenoma and cancer , 1998, The New England journal of medicine.

[21]  H. Esumi,et al.  Infrequent somatic mutation of the adenomatous polyposis coli gene in aberrant crypt foci of human colon tissue , 1998, Cancer.

[22]  L. Roncucci,et al.  K‐ras AND p53 MUTATIONS IN HUMAN COLORECTAL ABERRANT CRYPT FOCI , 1996, The Journal of pathology.

[23]  H. Esumi,et al.  Frequent and characteristic K-ras activation and absence of p53 protein accumulation in aberrant crypt foci of the colon. , 1995, Gastroenterology.

[24]  K. Kinzler,et al.  Molecular determinants of dysplasia in colorectal lesions. , 1994, Cancer research.

[25]  M. Ghia,et al.  Effect of aspirin on incidence and growth of aberrant crypt foci induced in the rat colon by 1,2-dimethylhydrazine. , 1994, Cancer letters.

[26]  A. Zauber,et al.  Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. , 1993 .

[27]  R. Bird,et al.  Aberrant crypts: potential preneoplastic lesions in the murine colon. , 1988, Cancer research.

[28]  R P Bird,et al.  Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. , 1987, Cancer letters.

[29]  Steven Gallinger,et al.  Transcriptional cooperation between the transforming growth factor-beta and Wnt pathways in mammary and intestinal tumorigenesis. , 2007, Cancer research.

[30]  P. Laird,et al.  DNA methylation profiles of female steroid hormone-driven human malignancies. , 2006, Current topics in microbiology and immunology.

[31]  U. G. Dailey Cancer,Facts and Figures about. , 2022, Journal of the National Medical Association.